Oncolytics also recently expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, positioning the company for ...

Spherix Global Insights reports new findings from its inaugural Market Dynamix(TM): PD-1 Inhibition in Solid Tumors (US) study, based on quantitative and qualitative responses from more than 100 U.S.

New research presented at ASCO GI positions both agents as potent therapeutic options, with potential to redefine standard ...

Researchers will use a quantitative continuous scoring platform to measure patients' tumors for TROP2 expression in the trial.

Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

Today, I live with cancer, but I don’t let it define me. I choose to define my story by courage, trust, and hope. I’ve ...

An insurance company decided that profits matter more than the life of a man who spent his career protecting this city,” said ...

ImmunityBio plans to establish a regional office in Saudi Arabia to support its expansion across the Middle East and North ...

Eikon Therapeutics, Inc. eyes IPO to fund EIK1001 oncology pipeline; early Phase 2 data show 60% response rate. Click for ...

QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, patients received the agent via subcutaneous injection every three weeks ...

(Alliance News) - Hutchmed China Ltd on Wednesday said the results from its SACHI phase-three lung cancer trial have been published in medical journal the Lancet.

ImmunityBio extended its winning streak to an 8th straight day on Tuesday, jumping 8.88 percent to finish at $2.82 apiece as ...